Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.

MLA

Blas, Leandro, et al. “Clinical Factors for Tumor Response, Progression, and Survival in Nivolumab for Advanced Renal Cell Carcinoma in the SNiP‐RCC Study.” International Journal of Urology, vol. 30, no. 9, Sept. 2023, pp. 788–96. EBSCOhost, https://doi.org/10.1111/iju.15265.

APA

Blas, L., Shiota, M., Miyake, H., Takahashi, M., Oya, M., Tsuchiya, N., Masumori, N., Matsuyama, H., Obara, W., Shinohara, N., Fujimoto, K., Nozawa, M., Ohba, K., Ohyama, C., Hashine, K., Akamatsu, S., Kamba, T., Mita, K., Gotoh, M., & Tatarano, S. (2023). Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study. International Journal of Urology, 30(9), 788–796. https://doi.org/10.1111/iju.15265

Chicago

Blas, Leandro, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, et al. 2023. “Clinical Factors for Tumor Response, Progression, and Survival in Nivolumab for Advanced Renal Cell Carcinoma in the SNiP‐RCC Study.” International Journal of Urology 30 (9): 788–96. doi:10.1111/iju.15265.